Wegovy: Complete Weight Loss Guide for 2026
Wegovy (semaglutide 2.4 mg) is the most prescribed FDA-approved weight loss injection in the U.S., with clinical trials showing 15–17% average body weight reduction. In 2026, Novo Nordisk launched an oral pill, a new high-dose 7.2 mg version (Wegovy HD), and Medicare coverage begins in July. This guide covers everything: cost, results, side effects, and how to get started.
Quick Answer
Wegovy helps you lose 15–17% of body weight (20.7% with the new HD dose). Cost ranges from $25/mo with insurance to $249/mo via subscription programs like Ro, WW, or LifeMD. An oral pill is now available. Medicare covers it at $50/mo starting July 2026.
What Is Wegovy?
Wegovy is the brand name for semaglutide 2.4 mg, an FDA-approved GLP-1 receptor agonist manufactured by Novo Nordisk specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition.
Semaglutide was originally approved as Ozempic for type 2 diabetes at a lower dose (up to 2.0 mg). Novo Nordisk then ran the STEP clinical trial program — one of the largest obesity drug trial programs ever — and proved the higher 2.4 mg dose produced significant weight loss. The FDA approved Wegovy for weight management in June 2021.
Wegovy works by mimicking the natural GLP-1 hormone your body produces after eating. It acts on receptors in the brain's appetite centers to reduce hunger, slow stomach emptying, and decrease “food noise” — the constant mental preoccupation with eating. Unlike many diet drugs of the past, GLP-1 medications address the biological drivers of obesity rather than simply suppressing appetite through stimulant effects.
For a deeper explanation of the mechanism, read our guide to how GLP-1 medications work and learn about food noise reduction.
How Much Weight Can You Lose on Wegovy?
Clinical trials show Wegovy produces 15–17% average body weight loss at the standard 2.4 mg dose, and 20.7% with the new Wegovy HD 7.2 mg dose. For a 250-pound person, that means losing 37–52 pounds over 12–18 months.
The landmark STEP 1 trial enrolled 1,961 adults with obesity and randomized them to either Wegovy 2.4 mg weekly or placebo for 68 weeks. The Wegovy group lost an average of 14.9% of body weight compared to 2.4% in the placebo group. Roughly one-third of participants lost more than 20% of their starting weight — results previously only achievable with bariatric surgery.
The STEP 5 trial demonstrated that weight loss can be maintained for at least two years with continued use. However, the STEP 1 extension study showed that stopping Wegovy leads to significant weight regain — approximately two-thirds of lost weight returned within one year of discontinuation.
Beyond weight loss, the SELECT trial proved Wegovy reduces major cardiovascular events by 20% in people with established heart disease — earning it an expanded FDA indication for cardiovascular risk reduction in March 2024.
Factors that influence your results include genetics, diet, exercise, and dose escalation speed. Combining Wegovy with resistance training can reduce muscle loss by up to 50% and improve body composition. Learn about optimal exercise strategies while on GLP-1 medications and what to know about preventing weight regain.
How Much Does Wegovy Cost in 2026?
Wegovy's list price is $1,349/month, but most people pay far less through insurance, savings cards, subscription programs, or the upcoming Medicare coverage.
Novo Nordisk offers the Wegovy Savings Cardfor commercially insured patients, which can bring the copay down to as low as $0–$25 per month. Patients without commercial insurance can use subscription telehealth programs that negotiate bulk pricing with pharmacies.
Starting July 1, 2026, the Medicare GLP-1 Bridge program will cover Wegovy at $50/month for Part D enrollees with BMI 30+ or BMI 27+ with weight-related conditions. Full coverage under the BALANCE Model begins January 2027. This is expected to benefit over 7 million Medicare beneficiaries.
Can You Take Wegovy as a Pill?
Yes. Novo Nordisk launched oral Wegovy (semaglutide tablets) in December 2025, making it the first oral formulation of a high-dose semaglutide for weight loss.
Oral Wegovy uses a proprietary absorption enhancer called SNAC that allows semaglutide to pass through the stomach lining. However, it requires specific dosing conditions: the pill must be taken on an empty stomach with no more than 4 ounces of water, and you must wait at least 30 minutes before eating, drinking, or taking other medications.
The oral formulation starts at approximately $149/month through subscription programs — less than the injection — making it an attractive option for patients who want a lower-cost entry point or dislike needles. Clinical trials showed comparable weight loss to the injectable form when patients reached equivalent doses.
For a detailed comparison of all oral GLP-1 options (including oral Wegovy, Rybelsus, and the new Foundayo/orforglipron), visit our oral GLP-1 comparison page. You can also read about Wegovy pill vs injection for a head-to-head breakdown.
What Is Wegovy HD?
Wegovy HD is the new 7.2 mg dose of semaglutide — triple the standard 2.4 mg dose — delivering 20.7% average weight loss, the highest of any single-agent GLP-1 medication.
Wegovy HD: 20.7% Weight Loss
The STEP UP 1 trial showed Wegovy HD (semaglutide 7.2 mg) achieved 20.7% average body weight loss at 68 weeks — closing the gap with tirzepatide (Zepbound) which shows 20–22%. This is the highest single-agent semaglutide result ever recorded, and it narrows the advantage dual-agonist drugs previously held.
Wegovy HD follows the same dose escalation as standard Wegovy but continues titrating beyond 2.4 mg to the 7.2 mg maintenance dose. Side effects are similar but slightly more common at the higher dose, particularly during dose increases.
What Is the Difference Between Wegovy and Ozempic?
Wegovy and Ozempic contain the exact same drug (semaglutide) made by the same company (Novo Nordisk), but they differ in dose, FDA approval, and intended use.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Generic Name | Semaglutide | Semaglutide |
| Max Dose | 2.4 mg (standard) / 7.2 mg (HD) | 2.0 mg |
| FDA Approval | Weight management | Type 2 diabetes |
| Avg Weight Loss | 15–17% (std) / 20.7% (HD) | 8–14% |
| Monthly List Price | $1,349 | $936 |
| Insurance Coverage | Varies (weight loss) | Most plans (diabetes) |
| Medicare (July 2026) | Covered at $50/mo | Already covered (diabetes) |
Because Wegovy has a higher maximum dose (2.4 mg vs 2.0 mg) and was specifically studied for weight loss in the STEP trial program, it produces greater average weight loss than Ozempic. However, many doctors prescribe Ozempic off-label for weight loss because it's often easier to get covered by insurance under the diabetes indication.
For a complete head-to-head analysis including insurance strategies, see our Ozempic vs Wegovy comparison. You can also compare Ozempic cost details with Wegovy cost details.
Is Wegovy or Zepbound Better for Weight Loss?
Zepbound (tirzepatide) produces slightly more weight loss (20–22%) than standard Wegovy (15–17%) because it targets both GLP-1 and GIP receptors. However, Wegovy HD (20.7%) has largely closed this gap.
Wegovy is a single-agonist (GLP-1 only), while Zepbound is a dual-agonist (GLP-1 + GIP). In the SURMOUNT trials, tirzepatide at its highest dose produced up to 22.5% average weight loss — the most of any obesity drug at the time. Standard Wegovy's STEP trials showed 15–17%, but the new Wegovy HD at 7.2 mg has pushed semaglutide results to 20.7%, making the two drugs much closer in efficacy.
Both medications have similar GI side effect profiles. The choice between them often comes down to insurance coverage, availability, and individual response. Some patients respond better to semaglutide, others to tirzepatide — there is no way to predict this in advance.
Read our detailed Wegovy vs Zepbound comparison for a complete analysis. You can also compare Zepbound pricing or explore Ozempic vs Mounjaro (the diabetes versions).
What Are the Side Effects of Wegovy?
The most common Wegovy side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Most improve within 4–8 weeks of starting treatment.
These side effects occur because Wegovy slows gastric emptying — the same mechanism that reduces appetite. The dose escalation protocol (starting at 0.25 mg and increasing monthly) is specifically designed to minimize GI symptoms. Most patients report side effects are worst during the first 2–4 weeks at each new dose level and then subside.
Serious but rare risks include pancreatitis (less than 1%), gallbladder problems (particularly gallstones during rapid weight loss), and a theoretical medullary thyroid carcinoma risk based on rodent studies. The FDA requires a boxed warning for thyroid C-cell tumors on all semaglutide medications. People with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take Wegovy.
Cosmetic concerns like “Ozempic butt” (sagging skin), “Ozempic face” (facial volume loss), and body changes from rapid weight loss affect some patients but are not medically dangerous.
For the complete side effect profile, read our GLP-1 side effects guide and check current FDA safety alerts. If you're experiencing issues, our managing side effects guide offers evidence-based strategies.
Where Can You Get Wegovy in 2026?
You can get Wegovy through your primary care doctor, an endocrinologist, or online telehealth subscription programs that include the prescription, medication, and ongoing support in one monthly fee.
GLP-1 programs with a price-lock guarantee and weight-loss promise
Comprehensive GLP-1 programs with multiple payout tiers
Personalized GLP-1 care with 24/7 specialist support from $149
Worried about scams? Use our scam checker tool to verify any provider. Also see our GLP-1 near me page to find providers available in your area.